NSCLC carboplatin net benefit pemetrexed prediction.
#NVALT 2 PLUS#
NVALT-7: ISRCTN38269072 (ISRCTN registry), GOIRC 02-2006: NCT00786331 (). nvALT est une amélioration au célèbre Notational Velocity: il en reprend les principales possibilités mais ajoute une louche de nouvelles possibilités qui la distingue de son. In this study, we developed and validated a prediction model for estimating absolute treatment effect of pemetrexed plus carboplatin versus single-agent pemetrexed in the second-line treatment of non-squamous non-small-cell lung cancer (NSCLC). Individualized prediction of treatment effect could be used to guide shared decision-making by discriminating patients who benefit most, to improve clinical outcome. There is important heterogeneity in the effects on PFS of pemetrexed-carboplatin versus pemetrexed in pretreated patients with advanced non-squamous NSCLC. The effects of pemetrexed-carboplatin can be predicted for individual patients based on routinely available patient and tumor characteristics. Decision curve analysis confirmed that the model adequately identified patients who benefit from pemetrexed-carboplatin, as prediction-based treatment led to improvement in net benefit with regard to PFS and overall survival when assuming a treatment threshold of 0-5 months gain in PFS, compared with other treatment strategies. External validation showed satisfactory calibration and moderate discrimination (C-index: 0.61, 95% confidence interval 0.56-0.67). Patients who benefited most included women, those with stage IV, high body mass index and/or adenocarcinoma. The applicability of the model for guiding clinical decision-making was evaluated using decision curve analysis.Ī wide distribution of predicted gain in median PFS by pemetrexed-carboplatin over pemetrexed was found, with a median of 0.7 months (interquartile range: -0.1 to 1.5 months). The model was externally validated in the GOIRC 02-2006 trial. Using data of relapsed patients with advanced non-squamous NSCLC from the NVALT-7 trial, a Weibull model for prediction of gain in median progression-free survival (PFS) by pemetrexed-carboplatin was derived based on patient and tumor characteristics. In this study, we developed and validated a prediction model for estimating absolute treatment effect of pemetrexed plus carboplatin versus single-agent pemetrexed in the second-line treatment of non-squamous non-small-cell lung cancer (NSCLC). Data from RCTs can be used for individualized treatment effect prediction, to identify patients who benefit from specific treatments.
#NVALT 2 DOWNLOAD#
You can download nvALT 2.Translating results from randomized clinical trials (RCTs) to individual patients in clinical practice is challenging, as treatment effects can vary substantially among individuals. In nvALT’s future, Terpstra promises better Lion support for fullscreen mode (shown in my screenshot but I’m using a SIMBL hack which you can find here), bouncy scrolling, and more. Personally I’m not so big about dumping webpages into nvALT, but the extensions are available to download from elastic threads. The extensions allow you to interact with webpages and links to dumps its textual contents or selection into the text editor - nvALT can run text through Instapaper’s mobilizer to clean up the results as text splashes into view. (Pretty nice eh?)Īlso available are browser extensions for Safari and Chrome that can get webpages and text into nvALT. A lot of hard work has gone into the latest release of nvALT, including better Multi-markdown 3 support (MMD3 has to be installed locally of course), a shortcut (⇧⌘L) for inserting links, Simplenote tag sync (which the author notes may choke on large note collections), the ability to pin the preview window when moving across apps (^⌘P then click the pin at the bottom of the window), and Textmate-like auto-pairing that will complete brackets for you as you type.
0 kommentar(er)
